LUNGevity Foundation
Prior to that, Dr. Shaw was the director of the Center for Thoracic Cancers at Massachusetts General Hospital and professor of medicine at Harvard Medical School. Dr. Shaw has performed clinical and translational research. Her clinical research has focused on subsets of NSCLC that have unique driver mutations, such as EGFR, ALK, and ROS1. Her translational research has focused on understanding and making clear the mechanisms of resistance to targeted therapies to develop novel combination treatment strategies. Dr. Shaw’s research has helped to develop numerous FDA-approved targeted therapies for patients with oncogene-driven NSCLC, such as crizotinib (Xalkori®) for patients with ALK or ROS1 rearrangements, and ceritinb (Zykadia®) and alectinib (Alecensa®) for patients with crizotinib-resistant, ALK-rearranged NSCLC.
This person is not in the org chart
This person is not in any offices
LUNGevity Foundation
2 followers
LUNGevity Foundation is the nation's leading lung cancer organization focused on improving outcomes for people with lung cancer through research, policy initiatives, education, support, and engagement for patients, survivors, and caregivers. LUNGevity seeks to make an immediate impact on quality of life and survivorship for everyone touched by the disease—while promoting health equity by addressing disparities throughout the care continuum. LUNGevity works tirelessly to advance research into early detection and more effective treatments, provide information and educational tools to empower patients and their caregivers, promote impactful public policy initiatives, and amplify the patient voice through research and engagement. The organization provides an active community for patients and survivors—and those who help them live longer and better lives.